(1)
Jost W. Therapie des idiopathischen Parkinson-Syndroms. Bremen: UNI-MED Verlag AG, 2017.
(2) Olanow CW, Kieburtz K, Odin P et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
(3) Lewitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord 2015;30:64-72.
(4) Olanow CW. Levodopa: effect on cell death and the natural history of Parkinson's disease.
Mov Disord 2015;30:37-44.
(5) Palhagen SE, Sydow O, Johansson A et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord 2016;29:17-23.
(6) Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
(7) Standaert DG, Rodriguez RL, Slevin JT et al. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract 2017;4:829-837.
(8) Senek M, Nyholm D. Continuous drug delivery in Parkinson's disease. CNS Drugs 2014;28:19-27.
(9) Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25:89-96.
(10) Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
(11) Stocchi F, Bonamartini A, Vacca L, Ruggieri S. Motor fluctuations in levodopa treatment:
clinical pharmacology. Eur Neurol 1996;36 Suppl 1:38-42.
52
(12) Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in thetreatment of Parkinson's disease. Nat Clin Pract Neurol 2006;2:382-392.
(13) Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-S7.
(14) Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371.
(15) Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
(16) Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
(17) Contin M, Riva R, Martinelli P et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990;13:19-28.
(18) Espay AJ, Lang AE. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. JAMA Neurol 2017;74:633-634.
(19) Nyholm D, Johansson A, Aquilonius SM, Hellquist E, Lennernas H, Askmark H. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Clin Neuropharmacol 2012;35:6-14.
(20) Nyholm D. Duodopa(R) treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18:916-929.
(21) Cenci MA, Ohlin KE, Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets 2011;10:670-684.
(22) Worth PF. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Pract Neurol 2013;13:140-152.
(23) Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009;9:859-867.
53
(24) Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion inadvanced Parkinson's disease. Mov Disord 2009;24:993-1000.
(25) Buhmann C, Hilker R, Lingor P et al. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm (Vienna ) 2017;124:1005-1013.
(26) Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: ef fi cacy, safety and patient selection.
Funct Neurol 2012;27:147-154.
(27) Volkmann J, Albanese A, Antonini A et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013;260:2701-2714.
(28) Antonini A, Stoessl AJ, Kleinman LS et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin 2018;34:2063-2073.
(29) "DUODOPA levodopa/carbidopa intestinal gel" Product Monograph.
https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/DUODOPA_PM_EN.pdf . 23-2-2018. 8401 Trans-Canada Highway St-Laurent, QCH4S 1Z1, AbbVie Corporation. Ref Type:
Online Source
(30) Lewitt PA, Nyholm D. New developments in levodopa therapy. Neurology 2004;62:S9-16.
(31) Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
(32) Bajenaru O, Ene A, Popescu BO et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. J Neural Transm (Vienna ) 2016;123:407-414.
(33) Zibetti M, Merola A, Artusi CA et al. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol 2014;21:312-318.
(34) Fernandez HH, Boyd JT, Fung VSC et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord 2018;33:928-936.
54
(35) Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinalinfusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
(36) Antonini A, Odin P, Opiano L et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm (Vienna ) 2013;120:1553-1558.
(37) Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
(38) Kurth MC, Tetrud JW, Tanner CM et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-1703.
(39) Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015;21:231-235.
(40) Slevin JT, Fernandez HH, Zadikoff C et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis 2015;5:165-174.
(41) Antonini A, Poewe W, Chaudhuri KR et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord 2017;45:13-20.
(42) Lopiano L, Modugno N, Marano P et al. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 2019;266:2164-2176.
(43) Antonini A, Fung VS, Boyd JT et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord 2016;31:530-537.
(44) Othman AA, Chatamra K, Mohamed ME et al. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Clin Pharmacokinet 2015;54:975-984.
55
(45) Murata M, Mihara M, Hasegawa K et al. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease. Ther Adv Neurol Disord 2018;11:1756286418759315.(46) Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015;21:231-235.
(47) Fernandez HH, Standaert DG, Hauser RA et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 2015;30:500-509.
(48) Kruger R, Lingor P, Doskas T et al. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. Adv Ther 2017;34:1741-1752.
(49) Antonini A, Poewe W, Chaudhuri KR et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord 2017;45:13-20.
(50) Slevin JT, Fernandez HH, Zadikoff C et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis 2015;5:165-174.
(51) Standaert DG, Rodriguez RL, Slevin JT et al. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract 2017;4:829-837.
(52) De FO, Dot J, Abu-Suboh M et al. Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. Brain Behav 2017;7:e00758.
(53) Pedersen SW, Clausen J, Gregerslund MM. Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic.
Open Neurol J 2012;6:37-50.
(54) Burack M, Aldred J, Zadikoff C et al. Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Mov Disord Clin Pract 2018;5:383-393.
(55) Willows T, Dizdar N, Nyholm D et al. Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted
56
Home Titration in Patients with Advanced Parkinson's Disease. J Parkinsons Dis 2017;7:719-728.(56) Amjad F, Bhatti D, Davis TL et al. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Adv Ther 2019;36:2233-2246.
(57) Vijiaratnam N, Hewer S, Varley S et al. Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention? Intern Med J 2018;48:469-471.
(58) Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
(59) "S3-Leitlinie Idiopathisches Parkinson-Syndrom" der Deutschen Gesellschaft für Neurologie.
https://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/030010_LL_langfassun g_ips_2016.pdf . 1-1-2016. Deutsche Gesellschaft für Neurologie. Ref Type: Online Source
(60) Pharmacoeconomic Review Report "LEVODOPA/CARBIDOPA (DUODOPA) (ABBVIE CORPORATION)". 2018. Ref Type: Online Source
(61) Lowin J, Sail K, Baj R et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease. J Med Econ 2017;20:1207-1215.
(62) Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W. Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. Neurodegener Dis Manag 2018;8:161-170.
(63) Ray CK, Antonini A, Robieson WZ, Sanchez-Solino O, Bergmann L, Poewe W. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. Eur J Neurol 2019;26:581-e43.
(64) Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. J Parkinsons Dis 2019;9:531-541.
(65) Mahajan A, Balakrishnan P, Patel A et al. Epidemiology of inpatient stay in Parkinson's disease in the United States: Insights from the Nationwide Inpatient Sample. J Clin Neurosci 2016;31:162-165.
57
(66) Baker JF, McClelland S, III, Line BG et al. In-Hospital Complications and Resource Utilization Following Lumbar Spine Surgery in Patients with Parkinson Disease: Evaluation of the National Inpatient Sample Database. World Neurosurg 2017;106:470-476.(67) Udd M, Lyytinen J, Eerola-Rautio J et al. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. Brain Behav 2017;7:e00737.
(68) Lew MF, Slevin JT, Kruger R et al. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord 2015;21:742-748.
(69) Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 1998;50:318.
(70) Robinson K, Dennison A, Roalf D et al. Falling risk factors in Parkinson's disease.
NeuroRehabilitation 2005;20:169-182.
(71) Rudzinska M, Bukowczan S, Stozek J et al. The incidence and risk factors of falls in Parkinson disease: prospective study. Neurol Neurochir Pol 2013;47:431-437.
(72) Ebersbach G, Ip CW, Klebe S et al. Management of delirium in Parkinson's disease. J Neural Transm (Vienna ) 2019;126:905-912.
(73) Aarsland D, Creese B, Politis M et al. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017;13:217-231.
(74) Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
(75) Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435-450.
(76) Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. J Neural Transm (Vienna ) 2017;124:1529-1537.
(77) Elkouzi A, Ramirez-Zamora A, Zeilman P et al. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Ann Clin Transl Neurol 2019;6:1989-1995.
58
(78) Cruse B, Morales-Briceno H, Chang FCF et al. 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease. NPJ Parkinsons Dis 2018;4:34.(79) Busk K, Nyholm D. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
Parkinsonism Relat Disord 2012;18:1000-1001
.
61
8. Erklärung nach §2 Abs. 2 Nr. 7 und 8 PromO
Ich erkläre, dass ich die der Medizinischen Hochschule Hannover zur Promotion eingereichte
Dissertation mit dem Titel „Welche Faktoren beeinflussen die Titration von Levodopa-Carbidopa Intestinal Gel-Therapie beim fortgeschrittenen idiopathischen Parkinson-Syndrom?“
in der Klinik für Neurologie mit Klinischer Neurophysiologie______________________________
unter Betreuung von Herrn PD Dr. med. Christoph Schrader__________________________________
mit der Unterstützung durch _____________________________________________________________
oder in Zusammenarbeit mit _____________________________________________________________
ohne sonstige Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die dort aufgeführten Hilfsmittel benutzt habe.
Die Gelegenheit zum vorliegenden Promotionsverfahren ist mir nicht kommerziell vermittelt worden.
Insbesondere habe ich keine Organisation eingeschaltet, die gegen Entgelt Betreuerinnen und Betreuer für die Anfertigung von Dissertationen sucht oder die mir obliegenden Pflichten hinsichtlich der Prüfungsleistungen für mich ganz oder teilweise erledigt.
Ich habe diese Dissertation bisher an keiner in- oder ausländischen Hochschule zur Promotion eingereicht. Weiterhin versichere ich, dass ich den beantragten Titel bisher noch nicht erworben habe.
Ergebnisse der Dissertation wurden/werden in folgendem Publikationsorgan
_________________________________________________________________ veröffentlicht.
Hannover, den _______________________
___________________________________
(Unterschrift)
62
9. Danksagung
Mein herzlicher Dank gilt meinem Betreuer, Herrn PD Dr. med. Christoph Schrader, der diese Studie initiierte, mir Mut machte und mich in jeder Phase der Studie unterstützte. Bei ihm konnte ich die Grundprinzipien der LCIG-Therapie und sowie die Betreuung der Patienten mit einem fortgeschrittenen Parkinson-Syndrom unter stationären und ambulanten Bedingungen erlernen.
Ferner möchte ich mich bei Frau Xiaofei Liu und Herrn Univ.-Prof. Dr. Armin Koch aus dem Institut für Biometrie der Medizinischen Hochschule Hannover bedanken, die mich bei der Durchführung und Auswertung der erhobenen Daten jederzeit unterstützt haben.
Ganz besonderer Dank gilt den Parkinson-Patienten, die ihre Zustimmung der Nutzung ihrer personenbezogenen Daten zur wissenschaftlichen und Forschungszwecken mitteilten und somit mir die Möglichkeit gaben, die oben dargestellte aufwendige Analyse durchführen zu können, was mir viel Freude bereitete.
63
10. Anhang
1. Hoehn & Yahr-Skala
Grad Hoehn-und-Yahr-Skala
I Einseitige Symptomatik mit fehlender oder nur geringer funktioneller Behinderung II Beidseitige Symptomatik, keine Haltungsinstabilität
III Beidseitige Symptomatik, geringe bis mäßige Behinderung mit leichter Haltungsinstabilität, noch körperlich selbstständig
IV Starke Behinderung, Patient aber ohne Hilfe steh- und gehfähig V Ohne Hilfe an Rollstuhl oder Bett gebunden
2. Äquivalenzdosen (nach Tomlinson 2010)
Medikamentenklasse Medikament Einzeldosen (mg/100 mg
L-DOPA)
L-DOPA L-DOPA (LD) 100
Retardiertes L-DOPA 133
Duodopa® 90
COMT-Inhibitoren* Entacapon LD x 0,33
Tolcapon LD x 0,5
Dopaminagonisten (non-Ergot) Pramipexol 1
Ropinirol 5
MAO-B-Inhibitoren Selegilin 10 mg (oral) 10
Selegilin 1,25 mg (sublingual) 1,25 retardiertem L-DOPA) mit dem entsprechenden Wert multipliziert. Für Stalevo® wird für L-DOPA und den COMT-Inhibitor die Dosis separat berechnet. Im British National Formular wird Selegilin 10mg oral als Äquivalenz zu 1,25 mg sublingual angegeben